These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31159699)

  • 1. Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies.
    Feeney O; Cockbain J; Morrison M; Diependaele L; Van Assche K; Sterckx S
    Am J Bioeth; 2018 Dec; 18(12):36-48. PubMed ID: 31159699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene patents, health care policy and licensing schemes.
    Caulfield T; von Tigerstrom B
    Trends Biotechnol; 2006 Jun; 24(6):251-4. PubMed ID: 16621074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Open Peer Commentaries on "Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies".
    Feeney O; Cockbain J; Morrison M; Diependaele L; Van Assche K; Sterckx S
    Am J Bioeth; 2019 Jan; 19(1):W10-W13. PubMed ID: 30676911
    [No Abstract]   [Full Text] [Related]  

  • 4. Patenting and licensing in genetic testing: ethical, legal, and social issues.
    Soini S; Aymé S; Matthijs G;
    Eur J Hum Genet; 2008 May; 16 Suppl 1():S10-50. PubMed ID: 18557182
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetics and Justice, Non-Ideal Theory and the Role of Patents: The Case of CRISPR-Cas9.
    Feeney O
    Eur J Health Law; 2022 Apr; 29(3-5):543-561. PubMed ID: 37582546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics.
    Aymé S; Matthijs G; Soini S;
    Eur J Hum Genet; 2008 May; 16 Suppl 1():S10-9. PubMed ID: 18432281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to: Listening behind the questions--how experts can improve the public discourse on gene patenting.
    Warburg RJ
    Pharmacogenomics; 2003 Jul; 4(4):509-10. PubMed ID: 12831328
    [No Abstract]   [Full Text] [Related]  

  • 8. Genes and patent policy: rethinking intellectual property rights.
    Andrews LB
    Nat Rev Genet; 2002 Oct; 3(10):803-8. PubMed ID: 12360238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The unexamined assumptions of intellectual property: adopting an evaluative approach to patenting biotechnological innovation.
    Gold ER; Adams W; Castle D; de Langavant GC; Cloutier LM; Daar AS; Glass A; Smith PJ; Bernier L
    Public Aff Q; 2004 Oct; 18(4):299-344. PubMed ID: 15812959
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulation as facilitation: negotiating the genetic revolution.
    Black J
    Mod Law Rev; 1998 Sep; 61(5):621-60. PubMed ID: 14518446
    [No Abstract]   [Full Text] [Related]  

  • 11. Much ado about gene patents: the role of foreseeability.
    Gulliford MJ
    Seton Hall Law Rev; 2004; 34(2):711-45. PubMed ID: 15115032
    [No Abstract]   [Full Text] [Related]  

  • 12. Waive CRISPR patents to meet food needs in low-income countries.
    van der Oost J; Fresco LO
    Nature; 2021 Sep; 597(7875):178. PubMed ID: 34489579
    [No Abstract]   [Full Text] [Related]  

  • 13. The fate and future of patents on human genes and genetic diagnostic methods.
    Huys I; Matthijs G; Van Overwalle G
    Nat Rev Genet; 2012 May; 13(6):441-8. PubMed ID: 22596320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction.
    Matthijs G; Aymé S
    Eur J Hum Genet; 2008 May; 16 Suppl 1():S1-2. PubMed ID: 18432280
    [No Abstract]   [Full Text] [Related]  

  • 15. Bioprospecting, genetic patenting and indigenous populations: challenges under a restructured information commons.
    Faye DJ
    J World Intellect Prop; 2004 May; 7(3):401-28. PubMed ID: 16755699
    [No Abstract]   [Full Text] [Related]  

  • 16. Patent protection for microbial technologies.
    Sherkow JS
    FEMS Microbiol Lett; 2017 Nov; 364(20):. PubMed ID: 29029027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does CRISPR-Cas open new possibilities for patents or present a moral maze?
    Webber P
    Nat Biotechnol; 2014 Apr; 32(4):331-3. PubMed ID: 24714479
    [No Abstract]   [Full Text] [Related]  

  • 18. Patenting DNA: who defines and protects the public good?
    Garcia SA
    Am J Bioeth; 2002; 2(3):25-6. PubMed ID: 12230850
    [No Abstract]   [Full Text] [Related]  

  • 19. DNA as patentable subject matter and a narrow framework for addressing the perceived problems caused by gene patents.
    Schilling SH
    Duke Law J; 2011 Dec; 61(3):731-73. PubMed ID: 22165443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brave new industry, that has such patents in it! Reflections on the economic consequences of patenting DNA.
    Cockburn IM
    Adv Genet; 2003; 50():385-98; discussion 507-10. PubMed ID: 14714701
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.